Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 4, 2011, Pages 712-722

  Turdi, Subat ^a   Kandadi, Machender R ^a   Zhao, Junxing ^a   Huff, Anna F ^a   Du, Min ^a   Ren, Jun ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

AMP activated protein kinase; Contraction; Morphology; Obesity

Indexed keywords

CARBON 14; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ISOENZYME; MAMMALIAN TARGET OF RAPAMYCIN; OLEIC ACID; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME DEFICIENCY; FATTY ACID OXIDATION; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE MUTATION; GLUCOSE INTOLERANCE; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOMEGALY; DIETARY FATS; ECHOCARDIOGRAPHY; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-PIM-1;

MUS; MUS MUSCULUS; TRITICUM AESTIVUM;

EID: 79952070936     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.12.007     Document Type: Article

References (50)

1. Eckel R.H., Barouch W.W., Ershow A.G. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 2002, 105:2923-2928.
2. Ren J., Ma H. Impaired cardiac function in leptin-deficient mice. Curr Hypertens Rep 2008, 10:448-453.
3. Sowers J.R. Obesity as a cardiovascular risk factor. Am J Med 2003, 115(Suppl 8A):37S-41S.
4. Feuvray D., Darmellah A. Diabetes-related metabolic perturbations in cardiac myocyte. Diab Metab 2008, 34(Suppl 1):S3-S9.
5. Boudina S., Abel E.D. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiol Bethesda 2006, 21:250-258.
6. Dong F., Li Q., Sreejayan N., et al. Metallothionein prevents high-fat diet induced cardiac contractile dysfunction: role of peroxisome proliferator activated receptor gamma coactivator 1alpha and mitochondrial biogenesis. Diabetes 2007, 56:2201-2212.
7. 2+ handling. Braz J Med Biol Res 2008, 41:615-620.
8. Ouwens D.M., Boer C., Fodor M., et al. Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 2005, 48:1229-1237.
9. Relling D.P., Esberg L.B., Fang C.X., et al. High-fat diet-induced juvenile obesity leads to cardiomyocyte dysfunction and upregulation of Foxo3a transcription factor independent of lipotoxicity and apoptosis. J Hypertens 2006, 24:549-561.
10. Sparks L.M., Xie H., Koza R.A., et al. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 2005, 54:1926-1933.
11. Hardie D.G. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes Lond 2008, 32(Suppl 4):S7-S12.
12. Merrill G.F., Kurth E.J., Hardie D.G., Winder W.W. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997, 273:E1107-E1112.
13. Hardie D.G. AMP-activated protein kinase: the guardian of cardiac energy status. J Clin Invest 2004, 114:465-468.
14. Russell R.R., Li J., Coven D.L., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004, 114:495-503.
15. Hwang J.T., Kwon D.Y., Park O.J., Kim M.S. Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr 2008, 2:323-326.
16. Zhang P., Hu X., Xu X., et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008, 52:918-924.
17. Steinberg G.R., Jorgensen S.B. The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini Rev Med Chem 2007, 7:519-526.
18. Viollet B., Andreelli F., Jorgensen S.B., et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 2003, 111:91-98.
19. Turdi S., Fan X., Li J., et al. AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. Aging Cell 2010, 9:592-606.
20. Oudit G.Y., Sun H., Kerfant B.G., et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004, 37:449-471.
21. Funai K., Cartee G.D. Inhibition of contraction-stimulated AMP-activated protein kinase inhibits contraction-stimulated increases in PAS-TBC1D1 and glucose transport without altering PAS-AS160 in rat skeletal muscle. Diabetes 2009, 58:1096-1104.
22. Chavez J.A., Roach W.G., Keller S.R., et al. Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation. J Biol Chem 2008, 283:9187-9195.
23. Mu J., Brozinick J.T., Valladares O., et al. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 2001, 7:1085-1094.
24. Gardin J.M., Siri F.M., Kitsis R.N., et al. Echocardiographic assessment of left ventricular mass and systolic function in mice. Circ Res 1995, 76:907-914.
25. Wang D., Patel V.V., Ricciotti E., et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci 2009, 106:7548-7552.
26. Doser T.A., Turdi S., Thomas D.P., et al. Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. Circulation 2009, 119:1941-1949.
27. Barger P.M., Brandt J.M., Leone T.C., et al. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000, 105:1723-1730.
28. Veerkamp J.H., Van Moerkerk H.T. The effect of malonyl-CoA on fatty acid oxidation in rat muscle and liver mitochondria. Biochim Biophys Acta 1982, 710:252-255.
29. Schaap F.G., Binas B., Danneberg H., et al. Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene. Circ Res 1999, 85:329-337.
30. Wang X., Wang R., Nemcek T.A., et al. A self-contained 48-well fatty acid oxidation assay1. Assay Drug Dev Technol 2004, 2:63-69.
31. Dong F., Kandadi M.R., Ren J., Sreejayan N. Chromium (d-phenylalanine)3 supplementation alters glucose disposal, insulin signaling, and glucose transporter-4 membrane translocation in insulin-resistant mice. J Nutr 2008, 138:1846-1851.
32. Cannon C.P. Obesity-related cardiometabolic complications. Clin Cornerstone 2008, 9:11-22.
33. Bertrand L., Horman S., Beauloye C., Vanoverschelde J.L. Insulin signalling in the heart. Cardiovasc Res 2008, 79:238-248.
34. Fujii N., Ho R.C., Manabe Y., et al. Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes 2008, 57:2958-2966.
35. Tian R., Musi N., D'Agostino J., et al. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001, 104:1664-1669.
36. Villena J.A., Viollet B., Andreelli F., et al. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes 2004, 53:2242-2249.
37. Beck J.S., O'Neill H.M., Hewitt K., et al. Reduced AMP-activated protein kinase activity in mouse skeletal muscle does not exacerbate the development of insulin resistance with obesity. Diabetologia 2009, 52:2395-2404.
38. Liu Y., Wan Q., Guan Q., et al. High-fat diet feeding impairs both the expression and activity of AMPKa in rats' skeletal muscle. Biochem Biophys Res Commun 2006, 339:701-707.
39. Kudo N., Barr A.J., Barr R.L., et al. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995, 270:17513-17520.
40. Xue B., Kahn B.B. AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 2006, 574:73-83.
41. McMullen J.R., Sherwood M.C., Tarnavski O., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
42. Dolinsky V.W., Chan A.Y.M., Frayne I R., et al. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009, 119:1643-1652.
43. Li S.Y., Fang C.X., Aberle N.S., et al. Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function. J Endocrinol 2005, 186:491-503.
44. Pedersen O., Kahn C.R., Flier J.S., Kahn B.B. High fat feeding causes insulin resistance and a marked decrease in the expression of glucose transporters (Glut 4) in fat cells of rats. Endocrinology 1991, 129:771-777.
45. Miura T., Suzuki W., Ishihara E., et al. Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes. Eur J Endocrinol 2001, 145:785-790.
46. Wright J.J., Kim J., Buchanan J., et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res 2009, 82:351-360.
47. Tian R., Abel E.D. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 2001, 103:2961-2966.
48. Sakamoto K., Holman G.D. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab 2008, 295:E29-E37.
49. Kramer H.F., Witczak C.A., Fujii N., et al. Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes 2006, 55:2067-2076.
50. Zhang Y., Ren J. Role of cardiac steatosis and lipotoxicity in obesity cardiomyopathy. Hypertension 2011, 57:148-150.